ECO Animal Health Group plc
("ECO" or the "Company")
Board Change
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Frank Armstrong has informed the Board of his intention to step down from his role as Independent Non-Executive Director of the Company, effective following the conclusion of this year's Annual General Meeting (AGM).
Dr Armstrong, who also serves as Chair of the Remuneration Committee, was recently elected as the Senior Lay Member (Chair) of the Court (Board) of the University of Edinburgh, a role he will assume in August 2026. Given the duties associated with this role and length of his tenure at ECO, Dr Armstrong has decided to retire from his position and will step down at the AGM, which is currently anticipated to be held in September.
The Board has commenced a thorough search process to identify a suitable replacement. Further updates will be provided in due course.
Dr Joachim Hasenmaier, Chairman of ECO Animal Health, commented: "On behalf of the Board, I would like to thank Frank for his invaluable contributions to ECO during his tenure as Independent Non-Executive Director and in his role as Chair of the Remuneration Committee. His counsel and expertise have been instrumental in supporting the Company through a significant period of growth. We wish him every success in his new role."
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson
|
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Jalini Kalaravy Samed Ethemi
|
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000
|
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
